(Q42824870)

8 November 2017

Early initiation of enzyme replacement therapy improves metabolic correction in the brain tissue of aspartylglycosaminuria mice (English)

1 reference

enzyme replacement therapy

8 November 2017

0 references

1 reference

Ulla Dunder

1

1 reference

8 November 2017

Pirjo Valtonen

series ordinal

2

1 reference

8 November 2017

Eira Kelo

series ordinal

3

1 reference

8 November 2017

Ilkka Mononen

series ordinal

4

1 reference

8 November 2017

language of work or name

1 reference

6 July 2010

1 reference

Journal of Inherited Metabolic Disease

8 November 2017

1 reference

8 November 2017

33

1 reference

8 November 2017

5

1 reference

8 November 2017

611-617

1 reference

https://scigraph.springernature.com/pub.10.1007/s10545-010-9158-7

8 November 2017

0 references

cites work

Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10545-010-9158-7

Detection of aspartylglycosaminuria using urine specimens recovered from absorbent filter paper

21 January 2018

1 reference

12 December 2020

Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I.

1 reference

12 December 2020

Assay of aspartylglycosylaminase by high-performance liquid chromatography.

1 reference

12 December 2020

Enzyme replacement therapy from birth in a feline model of mucopolysaccharidosis type VI.

1 reference

12 December 2020

A fluorometric assay for glycosylasparaginase activity and detection of aspartylglycosaminuria

1 reference

12 December 2020

The missing link in lysosomal enzyme targeting

1 reference

12 December 2020

Recombinant glycosylasparaginase and in vitro correction of aspartylglycosaminuria.

1 reference

12 December 2020

Enzyme replacement with recombinant beta-glucuronidase in murine mucopolysaccharidosis type VII: impact of therapy during the first six weeks of life on subsequent lysosomal storage, growth, and survival

1 reference

12 December 2020

Enzyme replacement therapy in a mouse model of aspartylglycosaminuria

1 reference

12 December 2020

Immune tolerance after long-term enzyme-replacement therapy among patients who have mucopolysaccharidosis I

1 reference

12 December 2020

A mouse model for the human lysosomal disease aspartylglycosaminuria.

1 reference

12 December 2020

The pharmacological chaperone N-butyldeoxynojirimycin enhances enzyme replacement therapy in Pompe disease fibroblasts

1 reference

12 December 2020

Enzyme replacement improves ataxic gait and central nervous system histopathology in a mouse model of metachromatic leukodystrophy

1 reference

12 December 2020

Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease

1 reference

12 December 2020

Clinical results of enzyme replacement therapy in Fabry disease: a comprehensive review of literature

1 reference

12 December 2020

Short-term, high dose enzyme replacement therapy in sialidosis mice

1 reference

12 December 2020

Uptake of alpha-(L)-iduronidase produced by retrovirally transduced fibroblasts into neuronal and glial cells in vitro

1 reference

12 December 2020

A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years.

1 reference

12 December 2020

Enzyme replacement therapy with idursulfase in patients with mucopolysaccharidosis type II.

1 reference

12 December 2020

Mannose 6-phosphate receptor-mediated transport of sulfamidase across the blood-brain barrier in the newborn mouse

1 reference

12 December 2020

Enzyme replacement in a canine model of Hurler syndrome

1 reference

12 December 2020

Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase).

1 reference

12 December 2020

Chemically modified beta-glucuronidase crosses blood-brain barrier and clears neuronal storage in murine mucopolysaccharidosis VII.

1 reference

12 December 2020

Enzyme replacement improves nervous system pathology and function in a mouse model for metachromatic leukodystrophy

1 reference

12 December 2020

Human acid alpha-glucosidase from rabbit milk has therapeutic effect in mice with glycogen storage disease type II

1 reference

12 December 2020

Enzyme replacement therapy in a feline model of MPS VI: modification of enzyme structure and dose frequency

1 reference

12 December 2020

Enzyme replacement therapy in mucopolysaccharidosis I: altered distribution and targeting of alpha-L-iduronidase in immunized rats

1 reference

12 December 2020

Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources

1 reference

12 December 2020

Overcoming the blood-brain barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII.

1 reference

12 December 2020

Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder.

1 reference

12 December 2020

Massive accumulation of Man2GlcNAc2-Asn in nonneuronal tissues of glycosylasparaginase-deficient mice and its removal by enzyme replacement therapy

1 reference

12 December 2020

Pompe disease: a review of the current diagnosis and treatment recommendations in the era of enzyme replacement therapy

1 reference

12 December 2020

Reversal of peripheral and central neural storage and ataxia after recombinant enzyme replacement therapy in alpha-mannosidosis mice

1 reference

12 December 2020

Advantages of using same species enzyme for replacement therapy in a feline model of mucopolysaccharidosis type VI

1 reference

12 December 2020

Lysosomal storage diseases: mechanisms of enzyme replacement therapy

1 reference

12 December 2020

Efficacy of enzyme replacement therapy in alpha-mannosidosis mice: a preclinical animal study

1 reference

12 December 2020

Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase

1 reference

12 December 2020

Developmentally regulated mannose 6-phosphate receptor-mediated transport of a lysosomal enzyme across the blood-brain barrier

1 reference

12 December 2020

Glycosaparaginase from human leukocytes. Inactivation and covalent modification with diazo-oxonorvaline.

1 reference

12 December 2020

10.1007/S10545-010-9158-7

Identifiers

DOI

1 reference

Dimensions Publication ID

8 November 2017

0 references

1 reference